Search results for "PHARMACOLOGY & PHARMACY"

showing 10 items of 329 documents

A novel technique for intraduodenal administration of drug suspensions/solutions with concurrent pH monitoring applied to ibuprofen formulations

2019

Characterization of dissolution of solid suspended drug particles in vivo is important for developing biopredictive in vitro tests. Therefore, methods to gain deeper insights into particle dissolution in vivo are needed. The soft Bioperm intubation method, a well established tool for investigation of permeability, absorption, metabolism, and drug interactions at predefined locations in the gastroinstinal tract, was modified. The novel intubation method involved pump-controlled infusion of pharmaceutical suspensions as well as simultaneous pH monitoring. This technique was used in a proof of concept study in healthy humans. Plasma sampling and non-compartmental analysis allowed comparison of…

AdultMaleDrugDuodenumDrug Compoundingmedia_common.quotation_subjectPharmaceutical ScienceCapsulesIbuprofen02 engineering and technology030226 pharmacology & pharmacyPh monitoringIntestinal absorptionYoung Adult03 medical and health sciences0302 clinical medicineSuspensionsPharmacokineticsIn vivomedicineHumansIntubation GastrointestinalDissolutionInfusion Pumpsmedia_commonChromatographyChemistryAnti-Inflammatory Agents Non-SteroidalGeneral MedicineHydrogen-Ion Concentration021001 nanoscience & nanotechnologyIbuprofenPharmaceutical SolutionsIntestinal AbsorptionFemaleParticle size0210 nano-technologyBiotechnologymedicine.drugEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.

2013

Granulocyte colony-stimulating factor (G-CSF) is often used in cancer patients receiving cytotoxic drugs to prevent or reduce high grade neutropenia. We propose a pharmacokinetic/pharmacodynamic model to describe myelotoxicity in both G-CSF treated and non-treated patients that shall increase our understanding of G-CSF effects. The model was built from absolute neutrophil counts (ANC) obtained in 375 carboplatin-treated patients, 47 of whom received G-CSF. It includes some prior information on G-CSF taken from the literature. Simulations were performed to understand differences in G-CSF effects and explore the impact of G-CSF formulation. Our model well described the data in all patients. M…

AdultMaleOncologymedicine.medical_specialtyNeutrophilsmedicine.medical_treatment[SDV]Life Sciences [q-bio]Pharmaceutical ScienceAntineoplastic AgentsNeutropeniaModels Biological030226 pharmacology & pharmacyCarboplatinLeukocyte CountYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticsNeoplasmsInternal medicineGranulocyte Colony-Stimulating FactormedicineHumansComputer SimulationPharmacology (medical)Young adultIntensive care medicinePrior informationAgedAged 80 and overPharmacologyChemotherapy[ SDV ] Life Sciences [q-bio]business.industryOrganic ChemistryCancerMiddle Agedmedicine.diseaseCarboplatin3. Good healthchemistry030220 oncology & carcinogenesisPharmacodynamicsMolecular MedicineFemalebusinessBiotechnology
researchProduct

Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS).

2019

Fabry's disease (FD) is an X-linked lysosomal storage disorder caused by the deficient activity of the lysosomal enzyme alpha-galactosidase A (alpha-Gal A) leading to intracellular accumulation of globotriaosylceramide (Gb3). Patients with amenable mutations can be treated with migalastat, a recently approved oral pharmacologic chaperone to increase endogenous alpha-Gal A activity. We assessed safety along with cardiovascular, renal, and patient-reported outcomes and disease biomarkers in a prospective observational multicenter study after 12 months of migalastat treatment under real-world conditions. Fifty-nine (28 females) patients (34 (57.6%) pretreated with enzyme replacement therapy) w…

AdultMalemedicine.medical_specialty1-DeoxynojirimycinTime FactorsGlobotriaosylceramideRenal function030226 pharmacology & pharmacyGastroenterologyVentricular Function Left03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineMigalastatGermanymedicineClinical endpointHumansPharmacology (medical)Genetic Predisposition to DiseaseProspective StudiesPharmacologySphingolipidsVentricular Remodelingbusiness.industryEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry's diseaseFabry diseaseBlood pressureTreatment Outcomechemistry030220 oncology & carcinogenesisalpha-GalactosidaseMutationFabry DiseaseFemaleGlycolipidsbusinessBiomarkersGlomerular Filtration RateClinical pharmacology and therapeutics
researchProduct

Handling forces for the use of different inhaler devices.

2019

Abstract Age and comorbidities can impact on the success of handling an inhaler. In this pilot study, we assessed finger strength in 62 participants (aged 5–17 years [n = 20], 18–65 years [n = 22] and > 65 years [n = 20]) by using different types of inhalers with integrated sensors (Respimat®, Breezhaler®, Aerolizer®, Genuair®, Diskus®, Ellipta®, HandiHaler®, Turbohaler® and a pressurized metered-dose inhaler [Atrovent®]). Parameters under investigation included the spontaneous and maximum achievable force and torque required to operate devices. Satisfaction with individual inhalers, and the relationship between satisfaction and strength, were also assessed. There was a marked difference in…

AdultMalemedicine.medical_specialtyAdolescentPharmaceutical SciencePilot Projects02 engineering and technology030226 pharmacology & pharmacyFingers03 medical and health sciencesYoung Adult0302 clinical medicineAge groupsRheumatic DiseasesAdministration InhalationMedicineHumansChildAgedAged 80 and overHand Strengthbusiness.industryInhalerNebulizers and VaporizersHealthy subjectsAge FactorsRheumatic diseaseEquipment DesignMiddle Aged021001 nanoscience & nanotechnologyPatient preferenceDry-powder inhalerPatient SatisfactionCase-Control StudiesChild PreschoolPhysical therapyFemale0210 nano-technologybusinessInternational journal of pharmaceutics
researchProduct

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.

2006

SUMMARY Background: Venlafaxine (V) is a mixed serotoninand noradrenaline reuptake inhibitor used as afirst-line treatment of depressive disorders. It ismetabolized primarily by the highly polymorphiccytochrome P450 (CYP) enzyme CYP2D6 to yielda pharmacologically active metabolite, O-des-methylvenlafaxine (ODV), and to a lesser extentby CYP3A4, to yield N-desmethylvenlafaxine(NDV).Objectives: The aim of this study was to assesswhether the O-demethylation phenotype of V hasan impact on the pharmacokinetics and clinicaloutcome.Method: In 100 patients treated with V, serumconcentrations of V, ODV and NDV and theratios of concentrations ODV/V as a measure ofO-demethylation were determined. Indiv…

AdultMalemedicine.medical_specialtyCYP2D6AdolescentGenotypeVenlafaxine HydrochlorideVenlafaxineBiology030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicineDesvenlafaxine SuccinateGenotypemedicineHumansPharmacology (medical)Active metaboliteAgedPharmacologyDepressive DisorderPolymorphism GeneticfungiVenlafaxine HydrochlorideMiddle AgedCyclohexanols3. Good healthEndocrinologyCytochrome P-450 CYP2D6PharmacogeneticsAntidepressive Agents Second-GenerationFemaleReuptake inhibitor030217 neurology & neurosurgeryPharmacogeneticsmedicine.drugJournal of clinical pharmacy and therapeutics
researchProduct

Factors associated with efficacy of an ibuprofen/pseudoephedrine combination drug in pharmacy customers with common cold symptoms

2016

SummaryAim The aim of this study was to explore factors affecting efficacy of treatment of common cold symptoms with an over-the-counter ibuprofen/pseudoephedrine combination product. Methods Data from an anonymous survey among 1770 pharmacy customers purchasing the combination product for treatment of own common cold symptoms underwent post-hoc descriptive analysis. Scores of symptoms typically responsive to ibuprofen (headache, pharyngeal pain, joint pain and fever), typically responsive to pseudoephedrine (congested nose, congested sinus and runny nose), considered non-specific (sneezing, fatigue, dry cough, cough with expectoration) and comprising all 11 symptoms were analysed. Multiple…

AdultMalemedicine.medical_specialtyCommon ColdInfectious DiseaseIbuprofenNonprescription DrugsPharmacy030226 pharmacology & pharmacyDrug Administration Schedule03 medical and health sciences0302 clinical medicineExpedited Clinical TrialSurveys and QuestionnairesInternal medicinemedicineHumans030223 otorhinolaryngologyNosePain Measurementbusiness.industryAnti-Inflammatory Agents Non-SteroidalCommon coldmultiple regression analysisGeneral MedicinePseudoephedrinemedicine.diseaseIbuprofenPseudoephedrinesymptom scoreNasal decongestantNasal DecongestantsTreatment Outcomemedicine.anatomical_structureAnesthesiaJoint painDrug Therapy CombinationFemalemedicine.symptombusinessmedicine.drugCombination drugInternational Journal of Clinical Practice
researchProduct

Sources of human plasma cyclic AMP. Examinations before and after beta 2 adrenergic stimulation.

1981

Plasma cyclic AMP was measured in different vessels in seventeen volunteers before and after stimulation with terbutaline. Differences between arterial blood and blood from the hepatic vein, right ventricle, inferior vena cava and a cubital vein could not be demonstrated. Only in the renal vein was the concentration of cyclic AMP decreased. Our results indicate that cyclic AMP is not generated from any specific isolated organ and that changes in cyclic AMP after subcutaneous injection of terbutaline reflect a general influence of this drug.

AdultMalemedicine.medical_specialtyInjections SubcutaneousTerbutalineStimulation030204 cardiovascular system & hematology030226 pharmacology & pharmacyBiochemistryInferior vena cava03 medical and health sciences0302 clinical medicineAdrenergic stimulationInternal medicineCyclic AMPTerbutalineMedicineHumansVeinAgedbusiness.industryBiochemistry (medical)Cell BiologyGeneral MedicineAdrenergic beta-AgonistsMiddle AgedStimulation Chemicalmedicine.anatomical_structureEndocrinologymedicine.veinVentriclecardiovascular systemArterial bloodRenal veinbusinessmedicine.drugThe Journal of international medical research
researchProduct

Cataracts and statins. A disproportionality analysis using data from VigiBase.

2019

The basis of the association between statin use and cataract has been explored using the World Health Organization (WHO) global database of individual case safety reports (ICSRs) for drug monitoring (VigiBase) through January 2019. The reporting odds ratios (RORs) as a measure of disproportionality for reported cataracts and individual statins have been calculated. Subgroup analyses according statin lipophilicity, sex, and age groups have been performed. Moreover, RORs have been calculated for non-statin lipid lowering drugs. An increased disproportionality have been found for most individual statins lovastatin: [ROR: 14.80, 95% confidence interval (CI): 13.30, 16.46)], atorvastatin (ROR: 3…

AdultMalemedicine.medical_specialtyStatinAdolescentmedicine.drug_classAtorvastatin010501 environmental sciencesToxicology030226 pharmacology & pharmacy01 natural sciencesRisk AssessmentCataract03 medical and health sciencesPharmacovigilanceYoung Adult0302 clinical medicineEzetimibeInternal medicinemedicineOdds RatioAdverse Drug Reaction Reporting SystemsHumansRosuvastatinChild0105 earth and related environmental sciencesAgedAged 80 and overbusiness.industryIncidenceGeneral MedicineOdds ratioMiddle AgedSimvastatinFemaleDrug MonitoringHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPravastatinmedicine.drugFluvastatinRegulatory toxicology and pharmacology : RTP
researchProduct

Pharmaceutical validation as a process of improving the quality of antineoplastic treatment

2006

Objective. To quantify the improvement added by standardization of pharmaceutical validation (PV) of antineoplastic treatment to the processes of prescription and preparation of the pharmacotherapeutic sequence, in terms of prevention and reduction of medication errors (ME). Design. Prospective cohort study during two years (from 2001-2002) for oncohaematologic patients (inpatients and outpatients) that compared the percentage of medication errors detected and resolved and the number of medication errors with potential clinical significance (severity value ≥4) intercepted during PV in both years. Results. During the PV processes, 202 ME were identified and resolved, which is the equivalent…

AdultMalemedicine.medical_specialtyTime FactorsAntineoplastic AgentsMedical Oncology030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineInternal medicineHumansMedication ErrorsMedicinePharmacology (medical)Clinical significanceProspective StudiesMedical prescriptionProspective cohort studyAgedAged 80 and overInpatientsbusiness.industryHematologyMiddle AgedPrognosisSurgeryOncologyPharmaceutical Services030220 oncology & carcinogenesisFemalePatient CarebusinessHospital UnitsTotal Quality ManagementJournal of Oncology Pharmacy Practice
researchProduct

Use of long acting injectable aripiprazole before and through pregnancy in bipolar disorder: a case report

2019

Abstract Background Long-acting injectable (LAI) antipsychotics for psychotic disorders provide advantages in treatment compliance, but data on their use in pregnancy are very limited. We present a clinical case of aripiprazole LAI use in pregnancy. Case presentation A 43-year-old woman diagnosed with bipolar disorder, with several relapses due to treatment interruption while trying to conceive. Finally, aripiprazole LAI treatment was planned by mutual agreement between doctor and the patient, who took aripiprazole LAI before and during pregnancy. She gave birth at 40 weeks to a 3500 g baby girl with no congenital malformations, who was healthy at 5 months after delivery. Conclusion As far …

AdultPediatricsmedicine.medical_specialtyTime FactorsBipolar disordermedicine.medical_treatmentvirusesAripiprazoleCase Report030226 pharmacology & pharmacyInjections IntramuscularAntipsychotic03 medical and health sciences0302 clinical medicineimmune system diseasesPregnancylcsh:RA1190-1270medicineHumansPharmacology (medical)Bipolar disorderAntipsychoticlcsh:Toxicology. PoisonsPharmacologyDosage FormsPregnancybusiness.industrylcsh:RM1-950Pregnancy Outcomevirus diseasesCongenital malformationsmedicine.diseasePregnancy ComplicationsLong actinglcsh:Therapeutics. PharmacologyTreatment interruptionLong-acting injectable aripiprazoleAripiprazoleFemaleClinical casebusinessmedicine.drugAntipsychotic AgentsFollow-Up StudiesBMC Pharmacology and Toxicology
researchProduct